Volume 9, Issue 2 (Vol.9 No.2 Jul 2020)                   rbmb.net 2020, 9(2): 223-229 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pouladi I, Mirnejad R, Rostampur S, Viesy S, Niakan M. Molecular Detection and Evaluation of MLـ Resistance M. Pneumoniae Associated with Mutation in 23S RNA Gene among Iranian Patients with Respiratory Infections. rbmb.net. 2020; 9 (2) :223-229
URL: http://rbmb.net/article-1-500-en.html
Department of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
Abstract:   (841 Views)
Background: Mycoplasma pneumoniae is a common cause of community-acquired pneumonia. The global increased resistance of M. pneumoniae strains to macrolide (ML) has become a worrisome health problem. The widespread use of these medications has led to increased rate of reported ML-resistant M. pneumoniae (MRMP) throughout the world. This study was aimed to evaluate the resistance of M. pneumoniae against erythromycin due to mutations in the 23S rRNA gene of patients with respiratory infections in Iran.

Methods: In this study, 100 samples of throat swab from a patient with respiratory problems were collected. After the cultured of all samples in M. pneumonia-specific PPLO medium, PCR technique was performed with specific primers. Afterwards, the broth micro-dilution MIC assay was employed. Finally, the PCR product of the 23S rRNA gene was sequenced to detect mutations of domain V in 23S rRNA gene of MRMP.

Results: It was found that 17 cases (17%) were positive for mycoplasma genus and six cases (6%) positive for M. pneumoniae species. Also, analysis of the sequence of 23S rRNA gene, revealed that one of the samples had mutations at positions A2431G and G2491A. All positive samples M. pneumoniae with 23S rRNA gene were sensitive to erythromycin.

Conclusions: These use of these antibiotics should be limited to prevent the emergence of MRMP in Iran.
Full-Text [PDF 223 kb]   (316 Downloads)    
Type of Article: Original Article | Subject: Microbiology
Received: 2020/05/18 | Accepted: 2020/06/21 | Published: 2020/10/7

1. Eshaghi A, Memari N, Tang P, Olsha R, Farrell DJ, Low DE, et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011. Emerg Infect Dis. 2013;19(9):1525-1527. [DOI:10.3201/eid1909.121466] [PMID] [PMCID]
2. Babaei Z, Pouladi I, Ashtari A, Azimi G, Niakan M. The Prevalence of Atypical Pneumonia Caused by Mycoplasma pneumoniae (P1 gene) in Patients with Respiratory Infections by Culture and Molecular PCR Methods in Tehran, Iran. Jundishapur Journal of Microbiology. 2019;12(11):e84174. [DOI:10.5812/jjm.84174]
3. Gdalevich M, Haas EJ, Dukhan L, Katz M, Zelenski V, Moran-Gilad J. Control of a Mycoplasma pneumoniae Outbreak in an Institutional Setting Using Azithromycin Prophylaxis. Front Public Health. 2017;5:366. [DOI:10.3389/fpubh.2017.00366] [PMID] [PMCID]
4. Xiao L, Ptacek T, Osborne J, Crabb D, Simmons W, Lefkowitz E, et al. Comparative genome analysis of Mycoplasma pneumoniae. BMC Genomics. 2015;16(1):610. [DOI:10.1186/s12864-015-1801-0] [PMID] [PMCID]
5. Zhang Y, Mei S, Zhou Y, Yang D, Pan T, Chen Z, et al. TIPE2 negatively regulates mycoplasma pneumonia-triggered immune response via MAPK signaling pathway. Nature.2017; 7(1): 13319. [DOI:10.1038/s41598-017-13825-y] [PMID] [PMCID]
6. Wang L, Feng Z, Zhao M, Yang S, Yan X, Guo W, et al. A comparison study between GeXP-based multiplex-PCR and serology assay for Mycoplasma pneumoniae detection in children with community acquired pneumonia. BMC Infect Dis. 2017;17(1):518. [DOI:10.1186/s12879-017-2614-3] [PMID] [PMCID]
7. Xu W, Guo L, Dong X, Li X, Zhou P, Ni Q, et al. Detection of Viruses and Mycoplasma pneumoniae in Hospitalized Patients with Severe Acute Respiratory Infection in Northern China, 2015-2016. Jpn J Infect Dis. 2018;71(2):134-139. [DOI:10.7883/yoken.JJID.2017.412] [PMID]
8. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Nationwide Surveillance of Macrolide-Resistant Mycoplasma pneumoniae Infection in Pediatric Patients. Antimicrobial Agents and Chemotherapy.2013;57(8):4046-4049. [DOI:10.1128/AAC.00663-13] [PMID] [PMCID]
9. Nakatani M, Shingo Mizunaga S, Takahata M, Nomura N. Inhibitory activity of garenoxacin against DNA gyrase of Mycoplasma pneumonia. J Antimicrob Chemother 2012;67(8):1850-2. [DOI:10.1093/jac/dks140] [PMID]
10. Meyer Sauteura P, Bleischa B, Voitb A, Maurerb F, Rellya C, Berger C, et al. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland. Swiss Med Wkly. 2014;144:w14041. [DOI:10.4414/smw.2014.14041]
11. Spuesens E, Meijer A, Bierschenk D, Hoogenboezem T, Donker G, Hartwig N, et al. Macrolide Resistance Determination and Molecular Typing of Mycoplasma pneumoniae in Respiratory Specimens Collected between 1997 and 2008 in The Netherlands. J Clin Microbiol. 2012;50(6):1999-2004. [DOI:10.1128/JCM.00400-12] [PMID] [PMCID]
12. Yin YD, Wang R, Zhuo C, Wang H, Wang MG, Xie CM, et al. Macrolide-resistant Mycoplasma pneumoniae prevalence and clinical aspects in adult patients with community-acquired pneumonia in China: a prospective multicenter surveillance study. J Thorac Dis. 2017; 9(10):3774-3781. [DOI:10.21037/jtd.2017.09.75] [PMID] [PMCID]
13. Hong JH, Chun JK, Uh Y, Oh KJ, Kim J, Yoon KJ. Two Cases of Mycoplasma pneumoniae Pneumonia with A2063G Mutation in the 23S rRNA Gene in Siblings. Ann Lab Med. 2013;33(1):65-68. [DOI:10.3343/alm.2013.33.1.65] [PMID] [PMCID]
14. Lee KE, Kim KW, Hong JY, Kim KE and Sohn MH. Modulation of IL 8 boosted by Mycoplasma pneumoniae lysate in human airway epithelial cells. J Clin Immunol. 2013;33(6):1117-1125. [DOI:10.1007/s10875-013-9909-y] [PMID]
15. Meyer Sauteur P, Unger W, Nadal D, Berger C, Vink C, Rossum A. Infection with and Carriage of Mycoplasma pneumoniae in Children. Front Microbiol. 2016;7:329. [DOI:10.3389/fmicb.2016.00329] [PMID] [PMCID]
16. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of Macrolide-Resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrobial Agents and Chemotherapy. 2013;57(3):1521-1523. [DOI:10.1128/AAC.02060-12] [PMID] [PMCID]
17. Izumikawa K, Izumikawa K, Takazono T, Kosai K, Morinaga Y, Nakamura S, et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20(3):181-5. [DOI:10.1016/j.jiac.2013.09.009] [PMID]
18. Saraya T. Mycoplasma pneumoniae infection: Basics. J Gen FAM Med, 2017;18(3):118-125. [DOI:10.1002/jgf2.15] [PMID] [PMCID]
19. Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study. Infect Chemother 2014;46(4):239-247. [DOI:10.3947/ic.2014.46.4.239] [PMID] [PMCID]
20. Guo DX, Hu WJ, Wei R, Wang H, Xu BP, Zhou W, et al. Epidemiology and mechanism of drug resistance of Mycoplasma pneumoniae in Beijing, China: A multicenter study. Bosn J Basic Med Sci. 2019;19(3):288-296. [DOI:10.17305/bjbms.2019.4053] [PMID] [PMCID]
21. Golmohammadi R, Ataee R A, Alishiri G H, Mirnejad R, Najafi A, Tate M, et al. Molecular Diagnosis of Mycoplasma pneumoniae in Synovial Fluid of Rheumatoid Arthritis Patients. Iranian Journal of Medical Microbiology. 2014; 8(1):1-8.
22. Liu X, Jiang Y, Chen X, Li J, Shi D, Xin D. Drug Resistance Mechanisms of Mycoplasma pneumoniae to Macrolide Antibiotics. Biomed Res Int. 2014;2014:320801. [DOI:10.1155/2014/320801] [PMID] [PMCID]
23. Wayne PA. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: 30th Informational Supplement. United Status: CLSI Document M100-S30; 2020.
24. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16(2):78-86. [DOI:10.1007/s10156-009-0021-4] [PMID]
25. Beikmohammadi H, Pouladi I, Zolfaghari MR, Niakan M. The Prevalence of 23S rRNA Mutations in ML-Resistant M. pneumoniae Isolates to Clarithromycin in Patients with Respiratory Infections. Reports of Biochemistry & Molecular Biology. 2020;9(2):157-162.
26. Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ, et al. Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. EuroSurveil. 2015;20(48):30078. [DOI:10.2807/1560-7917.ES.2015.20.48.30078] [PMID]
27. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013; 57(3):1521-3. [DOI:10.1128/AAC.02060-12] [PMID] [PMCID]
28. Bebear C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiol. 2011;6(4):423-31. [DOI:10.2217/fmb.11.18] [PMID]
29. Waites KB, Ratliff A, Crabb DM, Xiao L, Qin X, Selvarangan R, et al. Macrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol. 2019;57(11):e00968-19. [DOI:10.1128/JCM.00968-19] [PMID] [PMCID]
30. Zhang, W. Z, Zhang, S. J, Wang, Q. Y, Li, Y. D, Jing, H. B, Hu, G. Y, et al. Outbreak of macrolide-resistant Mycoplasma pneumoniae in a primary school in Beijing, China in 2018. BMC Infectious Diseases. 2019;19(1):871. [DOI:10.1186/s12879-019-4473-6] [PMID] [PMCID]
31. Guo D, Hu W, Xu B, Li J, Li D, Li S, et al. Allele-specific real-time PCR testing for minor macrolide-resistant Mycoplasma pneumoniae. BMC Infect Dis. 2019;19:616. [DOI:10.1186/s12879-019-4228-4] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb